LeMaitre Vascular (LMAT): How a Strong Q2 and Raised Guidance Are Shaping Its Valuation Outlook

LeMaitre Vascular (LMAT) delivered Q2 results that topped expectations, prompting the company to boost both revenue and earnings outlook for 2025. Management credits this move to the earlier than anticipated international rollout of Artegraft.

See our latest analysis for LeMaitre Vascular.

Despite a tough start to the year, LeMaitre Vascular’s latest international expansion news has fueled optimism that may help reverse fading momentum. The current share price sits at $86.05, reflecting a year-to-date drop, but a robust three-year total shareholder return of nearly 89% highlights the company’s long-term growth strength and resilience.

If headline-making results from medical device leaders have you looking for more, consider using our healthcare screener to discover innovative stocks making waves in the sector: See the full list for free.

With robust international growth now in the spotlight and shares trading below analyst price targets, investors may wonder if LeMaitre Vascular is offering rare value or if expectations for future gains are already built in.

Most Popular Narrative: 17.9% Undervalued

LeMaitre Vascular's most closely tracked narrative places its fair value at $104.78, comfortably above the current share price of $86.05. This signals that market sentiment is still catching up to the company's anticipated potential, according to consensus expectations.

Robust growth in international markets, particularly Europe and emerging regions, is being driven by new product launches (such as Artegraft and RestoreFlow) and ongoing regulatory approvals in countries like Germany, Ireland, Canada, Korea, and Singapore. This is establishing significant new revenue streams and underpinning future revenue growth.

Read the complete narrative.

Want to know which bold revenue expansion assumptions landed LeMaitre Vascular this premium price tag? The narrative hinges on aggressive international growth and earnings power that is considered unusual in the sector. Can the company really deliver on these ambitions? Dive in to see which forecasts make or break this valuation.

Result: Fair Value of $104.78 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the sustainability of recent pricing power and the risk of slower organic growth may challenge LeMaitre’s bullish long-term forecasts.

Find out about the key risks to this LeMaitre Vascular narrative.

Another View: Is the Market Already Pricing in Growth?

Looking beyond consensus forecasts, LeMaitre Vascular trades at a price-to-earnings ratio of 41.3x. That is much higher than the US Medical Equipment industry average of 29.5x, the peer group average of 35.1x, and even its own fair ratio of 18.2x. This marks the shares as expensive by nearly every comparison, raising the risk that expectations for future growth are already in the price. Could there be a downside if growth slows?

See what the numbers say about this price — find out in our valuation breakdown.

Build Your Own LeMaitre Vascular Narrative

If you want to dig deeper or craft your own story around LeMaitre Vascular's numbers, you can analyze the data yourself and share your perspective in just a few minutes. Do it your way.

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding LeMaitre Vascular.

Looking for More Smart Investment Opportunities?

Move quickly on fresh ideas to stay ahead in the market. Successful investors often act before the crowd notices the strongest trends and undervalued gems.

• Unlock potential future leaders by checking out these 892 undervalued stocks based on cash flows, which consistently show strong cash flows and attractive entry points.
• Capitalize on surging growth from emerging technologies with these 24 AI penny stocks, and see which companies are gaining the edge in artificial intelligence.
• Earn more from your portfolio by taking advantage of these 19 dividend stocks with yields > 3%, targeting stocks with robust yields and reliable payouts.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com